PMID- 9179063
OWN - NLM
STAT- MEDLINE
DCOM- 19970703
LR  - 20190620
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 79
IP  - 11
DP  - 1997 Jun 1
TI  - Prognostic significance of HER-2/neu gene amplification status by fluorescence in 
      situ hybridization of prostate carcinoma.
PG  - 2162-70
AB  - BACKGROUND: HER-2/neu gene amplification, established as a prognostic factor in 
      breast carcinoma and other cancers, has not been correlated with outcome in 
      prostate carcinomas (PCs). METHODS: HER-2/neu gene amplification was determined 
      by automated fluorescence in situ hybridization (FISH) using a unique sequence 
      cosmid probe on 113 formalin fixed, paraffin embedded 4-microns tissue sections 
      and the results compared with tumor grade, DNA ploidy, HER-2/neu protein 
      expression by immunohistochemistry (IHC), serum prostate specific antigen, 
      pathologic stage, and postoperative disease recurrence (mean follow-up of 44 
      months). RESULTS: HER-2/neu gene amplification by FISH (41% of PCs) correlated 
      with tumor grade (P = 0.001) and DNA ploidy status (P = 0.0003). HER-2/neu 
      protein overexpression by IHC (29% of PCs) correlated with grade (P = 0.03), but 
      not with DNA ploidy. A trend for similar HER-2/neu status in each PC by IHC and 
      FISH did not reach statistical significance (P = 0.25). On univariate analysis, 
      HER-2/neu amplification by FISH (P = 0.029), tumor grade (P = 0.013), and DNA 
      ploidy (P = 0.016) correlated with postoperative disease recurrence. HER-2/neu 
      expression by IHC did not correlate with outcome. On multivariate analysis, grade 
      (P = 0.0001) and ploidy (P = 0.001) were independent outcome predictors; 
      HER-2/neu amplification by FISH reached near-independent significance (P = 
      0.125). CONCLUSIONS: HER-2/neu gene amplification by FISH on archival PCs 
      significantly correlates with grade and DNA ploidy status, is more sensitive than 
      IHC in detecting HER-2/neu gene abnormalities, predicts postoperative disease 
      recurrence, and may prove important in planning therapy for patients with 
      prostate carcinoma.
FAU - Ross, J S
AU  - Ross JS
AD  - Department of Pathology and Laboratory Medicine, Albany Medical College, New York 
      12208, USA.
FAU - Sheehan, C E
AU  - Sheehan CE
FAU - Hayner-Buchan, A M
AU  - Hayner-Buchan AM
FAU - Ambros, R A
AU  - Ambros RA
FAU - Kallakury, B V
AU  - Kallakury BV
FAU - Kaufman, R P Jr
AU  - Kaufman RP Jr
FAU - Fisher, H A
AU  - Fisher HA
FAU - Rifkin, M D
AU  - Rifkin MD
FAU - Muraca, P J
AU  - Muraca PJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (DNA, Neoplasm)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adenocarcinoma/classification/*pathology
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/pathology
MH  - DNA, Neoplasm/analysis
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Ploidies
MH  - Prognosis
MH  - Prostate-Specific Antigen/blood
MH  - Prostatectomy
MH  - Prostatic Neoplasms/classification/*pathology
MH  - Receptor, ErbB-2/*analysis/genetics
EDAT- 1997/06/01 00:00
MHDA- 2000/06/20 09:00
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1997/06/01 00:00 [entrez]
AID - 10.1002/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U [pii]
AID - 10.1002/(sici)1097-0142(19970601)79:11<2162::aid-cncr14>3.0.co;2-u [doi]
PST - ppublish
SO  - Cancer. 1997 Jun 1;79(11):2162-70. doi: 
      10.1002/(sici)1097-0142(19970601)79:11<2162::aid-cncr14>3.0.co;2-u.